Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16181383 | 0.98 | ALDH1A1 (0.32) | CNR1PDE4BALDH1A1 | |
| SCHEMBL16181377 | 0.90 | PIK3CD (0.32) | — | |
| SCHEMBL16181419 | 0.83 | RIPK1 (0.33) | — | |
| SCHEMBL6903033 | 0.81 | PLG (0.36) | CNR1 | |
| SCHEMBL10308826 | 0.77 | IDH1 (0.34) | CNR1PDE4BPDE4DALDH1A1 | |
| SCHEMBL10308827 | 0.74 | PIK3CD (0.34) | — | |
| SCHEMBL10308930 | 0.69 | GRM5 (0.35) | ALDH1A1 | |
| SCHEMBL14114609 | 0.69 | GRM5 (0.35) | ALDH1A1 | |
| SCHEMBL12266202 | 0.69 | — | — | |
| SCHEMBL22212594 | 0.67 | GAA (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| EP-1032561-B1 | SUBSTITUTED OXIMES AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| CN-1122022-C | Substituted oximes as neurokinin antagonists | SCHERING CORP (US) | 2003-09-24 | — | — | CN | disclosed |
| CN-1279670-A | Substituted oximes as neurokinin antagonists | SCHERING CORP (US) | 2001-01-10 | — | — | CN | disclosed |
| EP-1032561-A1 | SUBSTITUTED OXIMES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 2000-09-06 | — | — | EP | disclosed |
| US-6063926-A | HAVING GREATER BIOACTIVITY | SCHERING CORPORATION (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999026924-A1 | SUBSTITUTED OXIMES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | CNR1 2305/4885PDE4B 2944/4885PDE4D 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.